RETEVMO vs TASIGNA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 17, 2026·How we rate

Possible drug interaction. RETEVMO and TASIGNA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	RETEVMO	TASIGNA
Rating	New	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	SELPERCATINIB	NILOTINIB HYDROCHLORIDE
Manufacturer	Eli Lilly and Co	Novartis
Dosage forms	Capsule, Tablet	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

retevmo tasigna

Rating

New

70/100

Pharmacy pays

—

Type

Active ingredient

SELPERCATINIB

NILOTINIB HYDROCHLORIDE

Manufacturer

Eli Lilly and Co

Novartis

Dosage forms

Capsule, Tablet

Capsule

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

Frequently asked questions

What is the difference between Retevmo and Tasigna?

Retevmo contains Selpercatinib, while Tasigna contains Nilotinib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.